LQDA.NASDAQLiquidia CORP

Form 4: Liquidia Corp's Chief Medical Officer Rajeev Saggar Reports Stock Sale to Cover Taxes

Sentiment:

SEC Form 4 Filing


Rajeev Saggar, Chief Medical Officer of Liquidia Corp, reports selling 1,525 shares of common stock to cover taxes associated with the settlement of restricted stock units.

Summary

  • On April 12, 2024, Rajeev Saggar, the Chief Medical Officer of Liquidia Corp, sold 1,525 shares of common stock at a price of $14.58 per share.
  • The sale was executed to cover taxes associated with the settlement of restricted stock units (RSUs) that were initially granted on January 11, 2023.
  • Following the transaction, Saggar directly owns 213,321 shares of Liquidia Corp, which includes unvested RSUs and shares acquired through the Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: This is a neutral transaction related to tax obligations, with no indication of positive or negative sentiment towards the company's prospects.

Industry Context

Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company insiders. This filing indicates that the Chief Medical Officer is selling shares to cover tax obligations, which is a common practice.

Comparison to Industry Standards

  • Form 4 filings are standard practice for publicly traded companies and their insiders, as mandated by the SEC.
  • The sale of shares to cover tax obligations related to RSU vesting is a common occurrence among executives in publicly traded companies.
  • There are no specific industry benchmarks for this type of transaction, as it is dependent on individual compensation structures and tax liabilities.

Key Dates

DateDescription
July 18, 2022Date of initial grant of 93,834 RSUs, of which 35,188 remain unvested.
January 11, 2023Date of initial grant of 83,333 RSUs, of which 57,291 remain unvested; also date of RSU settlement requiring tax coverage.
December 15, 2023Date the Reporting Person adopted a Rule 10b5-1 plan.
January 11, 2024Date of grant of 56,492 RSUs, none of which have vested as of the date of this Form 4.
April 12, 2024Date of the transaction (sale of 1,525 shares).
April 16, 2024Date of signature on the Form 4 filing.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.